Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Particulate form
Reexamination Certificate
2007-06-05
2007-06-05
Hui, San-ming (Department: 1617)
Drug, bio-affecting and body treating compositions
Preparations characterized by special physical form
Particulate form
C424S401000, C424S490000
Reexamination Certificate
active
10935506
ABSTRACT:
A combination of a pro-agonist first medication in timed release form, and a sequestered second non-antagonist medication allows the first medication to be effective if taken according to medical directions. If the combination is tampered with or otherwise taken in a manner not according to medical directions, the second medication is released and prevents the first medication from becoming effective. The non-antagonist second medication does not precipitate immediate withdrawal in a dependent patient.
REFERENCES:
patent: 5236714 (1993-08-01), Lee et al.
patent: 5611971 (1997-03-01), Maedera et al.
patent: 6124282 (2000-09-01), Sellers et al.
patent: 6280771 (2001-08-01), Monkhouse et al.
patent: 6482440 (2002-11-01), Zemlan et al.
patent: 6696088 (2004-02-01), Oshlack et al.
patent: 6725118 (2004-04-01), Fried et al.
patent: 2002/0107259 (2002-08-01), Burch et al.
patent: 2003/0091635 (2003-05-01), Baichwal et al.
patent: 2003/0118641 (2003-06-01), Maloney et al.
patent: 2003/0124061 (2003-07-01), Roberts
patent: 2004/0052731 (2004-03-01), Hirsh et al.
patent: 2004/0058946 (2004-03-01), Buchwald et al.
patent: 2004/0110781 (2004-06-01), Harmon et al.
patent: 2004/0131552 (2004-07-01), Boehm
patent: 2004/0241218 (2004-12-01), Tavares et al.
patent: WO 01/58451 (2001-08-01), None
Journal of Oncology, 2002;20(9):2409-2410.
Kaplan et al. Journal of Pharmacology and Experimental Therapeutics, 1997, 281(1):103-108.
Weinhold, et al., “Buprenorphone Alone and in Combination with Naloxone in Non-Dependent Humans,” Drug and Alcohol Dependence 30:263-274 (1992).
Mendelson, et al., “Buprenorphone and Naloxone Interactions in Opiate-Dependent Volunteers”, Clin. Pharm. Ther. 60:105-114 (1996).
Patt, et al., “Using Controlled-Release Oxycodone for the Management of Chronic Cancer and Noncancer Pain”, The American Pain Society Bulletin 6(4) (Jul./Aug. 1996).
Hui San-ming
PharmoRx Inc.
Sutherland & Asbill & Brennan LLP
LandOfFree
Material for controlling diversion of medications does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Material for controlling diversion of medications, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Material for controlling diversion of medications will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3827321